Loading…
← CockpitCompetitor Analysis › 002644.SZ Lanzhou Foci Pharmaceutical Co., Ltd. Class AOpen in the cockpit ↗

Lanzhou Foci Pharmaceutical Co., Ltd. Class A002644.SZCompetitor analysis, valuation and peers

China · CNY·Health Care›Pharmaceuticals: Other
Momentum strong 63
Mkt cap
$548M
US dollars, full cap
Free float
38%
of shares outstanding
$/day
$4.50M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-2.7 pp
WACC 8.7%
Hurdle
+9 pp
Req g minus delivered
Close · CNYCN¥7.17
1D-2.3%
1W-4.8%
1M-10.2%
3M-18.5%
6M-8.7%
YTD-17.0%
1Y-21.1%
ATR %2.9%
52w lowhigh34.9% off high

What Lanzhou Foci Pharmaceutical does

Employees: 1,332

Lanzhou Foci Pharmaceutical at a glance

Size Lanzhou Foci Pharmaceutical (002644.SZ) is a China Health Care company (Pharmaceuticals: Other) with a market value of $548M, the 3471st largest of 4,790 China companies the cockpit tracks. Shares closed at CN¥7.17 on 18 Nov 2026.

Performance Over six months the shares fell 8.7%, against -22.9% for the median peer and -20.0% for the China market (cap-weighted) — 6th highest of 21 in its peer set.

Growth Revenue grew 6.1% over the last twelve months (peer median -3.0%); the operating margin is 6.2% (peer median 12.2%).

Valuation It trades at 3.3× enterprise value to sales against a peer median of 2.9× (8th most expensive of 20).

Price implies For today's price to make sense, revenue must grow about 15% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is +9 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.

Capital Return on invested capital runs 2.7 points below its cost of capital (8.7% WACC).

Relative performance

8010021 May 202621 Aug 202618 Nov 2026002644.SZ 92Peer median 77
Six months, rebased to 100: Lanzhou Foci Pharmaceutical against the median of its 20 peers (local-currency closes).

Lanzhou Foci Pharmaceutical financials

Reported figures in CNY; fiscal year ends 2025-12-31. TTM = trailing twelve months.
TTMFY2025FY2024FY2023FY2022
RevenueCN¥942MCN¥909MCN¥966MCN¥1.16BCN¥1.04B
Revenue growth—-6%-17%+12%—
Gross profitCN¥347MCN¥284MCN¥266MCN¥337MCN¥284M
EBITDAn/aCN¥98.5MCN¥95.5MCN¥122MCN¥115M
Net incomeCN¥61.8MCN¥49.2MCN¥60.1MCN¥67.2MCN¥109M
Free cash flowCN¥248MCN¥165MCN¥26.9MCN¥45.0MCN¥45.8M
Capital expenditureCN¥35.2MCN¥18.5MCN¥13.3MCN¥22.5MCN¥41.5M
Total debtCN¥75.9MCN¥98.4MCN¥88.4MCN¥80.1MCN¥57.9M

Quarterly statements and history in the cockpit →

Lanzhou Foci Pharmaceutical competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-40%-20%0%-20%0%002412AVBP30150730026107756036693001583174500025623000396004883007912877BOI6032620460PHN002644.SZ6-month return →1-month return →
Up and to the right = strong over both horizons. Lanzhou Foci Pharmaceutical is the large dot.

Fundamentals: revenue growth against valuation

-20%0%+20%0×2.5×5×7.5×0024123015073002610775603669300158317450002562300039600488002826300791BOI60326204601707PHN002644.SZRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. Lanzhou Foci Pharmaceutical is the large dot.

Capital: growth delivered against growth the price implies

-20%-10%0%+10%+20%-20%0%20%002412301507002562300039600488002826300791BOI6032621707PHN002644.SZGrowth delivered (Del g) →Growth the price implies (Req g, 7 yrs) →
Above the diagonal = the price needs more growth than the company has been delivering; below = the price already allows for a slowdown. Lanzhou Foci Pharmaceutical is the large dot.

Lanzhou Foci Pharmaceutical competitors and peer comparison

How Lanzhou Foci Pharmaceutical compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

Lanzhou Foci Pharmaceutical against its 20 peers (data as of 18 Nov 2026)
Measure002644.SZPeer medianRank in peer set
1-month return-10.2%-10.8%10th highest of 21
6-month return-8.7%-22.9%6th highest of 21
Distance from 52-week high-34.9%-46.5%4th highest of 21
Revenue growth (TTM)+6.1%-3.0%7th highest of 19
Operating margin6.2%12.2%10th lowest of 21
EV / Sales3.3×2.9×8th most expensive of 20
Growth the price implies (Req g, 7 yrs)15.4%1.8%3rd most demanding of 13
Growth delivered (Del g)+6.5%+7.0%6th lowest of 12
Hurdle (Req g minus delivered)+8.9 pp-1.4 pp2nd most demanding of 12
ROIC minus cost of capital-2.7 pp-0.1 pp6th lowest of 20

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
Lanzhou Foci Pharmaceutical 002644.SZChina$548M-9%+6%6%3.3×15.4%+6.5%
Hunan Hansen Pharmaceutical 002412.SZChina$532M-2%-4%21%3.0×1.4%+7.0%
ArriVent BioPharma AVBPUnited States$564M-60%n/a-3,620%34.2×n/an/a
Hangzhou Minsheng Healthcare 301507.SZChina$583M-23%+21%11%3.8×19.1%+12.1%
ABA Chemicals 300261.SZChina$592M-26%-16%-23%4.9×n/an/a
CK Life Sciences International (Holdings) 0775.HKHong Kong$613M-30%0%0%2.0×n/an/a
Lionco Pharmaceutical 603669.SSChina$474M+4%-6%-17%8.4×n/an/a
Shanxi Zhendong Pharmaceutical 300158.SZChina$641M-22%-28%-25%1.8×n/an/a
Myung in Pharm 317450.KSSouth Korea$466M-20%+7%35%0.7×n/an/a
Brother Enterprises 002562.SZChina$668M-33%+8%4%1.5×4.0%+13.5%
Shanghai Kaibao Pharmaceutical 300039.SZChina$703M-20%-14%22%3.4×0.4%+4.8%
Tianjin Tianyao Pharmaceuticals 600488.SSChina$718M-36%-12%3%2.2×2.1%-1.3%
Tibet Aim Pharm 002826.SZChina$407M-22%+13%14%2.9×0.4%+1.0%
Sirio Pharma 300791.SZChina$759M-6%-9%1%1.5×14.1%+15.6%
China Shineway Pharmaceutical 2877.HKHong Kong$760M-8%-18%25%n/an/an/a
Boiron BOI.PAFrance$367M-31%-2%5%0.6×-0.8%-0.5%
TSI 603262.SSChina$842M-46%+3%14%4.6×24.3%+13.4%
Sihuan Pharmaceutical 0460.HKHong Kong$856M-34%+30%15%2.1×n/an/a
Daiken Biomedical 7780.TWTaiwan$342M-19%n/a18%3.0×-1.6%n/a
Grape King Bio 1707.TWTaiwan$342M-27%-5%19%1.0×-17.2%+2.3%
PharmaNutra PHN.MIItaly$922M+2%+17%22%5.6×4.7%+18.5%

Questions

Which companies are Lanzhou Foci Pharmaceutical's closest peers?
The cockpit's peer set: Hunan Hansen Pharmaceutical (002412.SZ), ArriVent BioPharma (AVBP), Hangzhou Minsheng Healthcare (301507.SZ), ABA Chemicals (300261.SZ), CK Life Sciences International (Holdings) (0775.HK), Lionco Pharmaceutical (603669.SS), Shanxi Zhendong Pharmaceutical (300158.SZ), Myung in Pharm (317450.KS).
Is Lanzhou Foci Pharmaceutical expensive compared with its peers?
On ev / sales it trades at 3.3× against a peer median of 2.9×, 8th most expensive of 20 in its peer set. For today's price to make sense, revenue must grow about 15% a year for seven years (Req g). Recent delivered growth is +6%, so the hurdle is +9 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
How has Lanzhou Foci Pharmaceutical stock performed?
Over six months to 18 Nov 2026 the shares returned -8.7% against -22.9% for the median peer; over one year -21.1%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.